A New Chapter, A New CEO For Dendreon
This article was originally published in The Pink Sheet Daily
Former Savient and ImClone CEO Johnson will be responsible for driving commercial expansion of Provenge in the U.S. and Europe. Mitchell Gold steps down as CEO after successfully getting the prostate cancer drug to market following an arduous FDA review but struggling with commercial complexities.
You may also be interested in...
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
With other companies struggling to develop new gout therapies, Savient is hoping to develop a partnering strategy for Krystexxa in markets outside the U.S. as well as broaden use of the injectable biologic in different categories of patients.
New top leadership at Caisson Biotech, Kala Pharmaceuticals and BASi; Cubist Pharmaceuticals announces a pair of promotions; FDA hires a director for the Office of Generic Drugs; more personnel announcements in this month’s column.